AMACR Antikörper
-
- Target Alle AMACR Antikörper anzeigen
- AMACR (alpha-Methylacyl-CoA Racemase (AMACR))
-
Reaktivität
- Human
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser AMACR Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunocytochemistry (ICC)
- Verwendungszweck
- AMACR Antibody
- Aufreinigung
- Ascitic fluid
- Immunogen
- Purified recombinant fragment of human AMACR expressed in E. Coli.
- Klon
- 2A10F3
- Isotyp
- IgG2b
- Top Product
- Discover our top product AMACR Primärantikörper
-
-
- Applikationshinweise
-
ELISA: 1/10000
ICC: 1/200 - 1/1000
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- Ascitic fluid containing 0.03 % sodium azide.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
-
-
Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo." in: Cancer letters, Vol. 244, Issue 2, pp. 274-88, (2006) (PubMed).
: "Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care." in: The Journal of urology, Vol. 175, Issue 3 Pt 1, pp. 820-34, (2006) (PubMed).
: "
-
Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo." in: Cancer letters, Vol. 244, Issue 2, pp. 274-88, (2006) (PubMed).
-
- Target
- AMACR (alpha-Methylacyl-CoA Racemase (AMACR))
- Andere Bezeichnung
- AMACR (AMACR Produkte)
- Synonyme
- AMACR antikoerper, DKFZp469O1232 antikoerper, amacr antikoerper, NCU04099.1 antikoerper, MGC89832 antikoerper, AMACRD antikoerper, CBAS4 antikoerper, RACE antikoerper, RM antikoerper, Macr1 antikoerper, Da1-8 antikoerper, Marc1 antikoerper, alpha-methylacyl-CoA racemase antikoerper, PROBABLE ALPHA-METHYLACYL-COA RACEMASE MCR (2-methylacyl-CoA racemase) (2-arylpropionyl-CoA epimerase) antikoerper, Alpha-methylacyl-CoA racemase antikoerper, alpha-methylacyl-CoA racemase L homeolog antikoerper, AMACR antikoerper, mcr antikoerper, BPSL0064 antikoerper, Maqu_2037 antikoerper, UREG_03852 antikoerper, MCYG_01809 antikoerper, amacr antikoerper, amacr.L antikoerper, MGYG_04259 antikoerper, NCU04099 antikoerper, Amacr antikoerper
- Hintergrund
-
Description: AMACR (alpha-methylacyl-CoA racemase) has been recently described as prostate cancer-specific gene that encodes a protein involved in the beta-oxidation of branched chain fatty acids. Expression of AMACR protein is found in prostatic adenocarcinoma but not in benign prostatic tissue. It stains premalignant lesions of prostate: high-grade prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia. AMACR can be used as a positive marker for PIN. Defects in AMACR are the cause of congenital bile acid synthesis defect type 4 (CBAS4), also known as cholestasis, intrahepatic, with defective conversion of trihydroxycoprostanic acid to cholic acid or trihydroxycoprostanic acid in bile. Clinical features include neonatal jaundice, intrahepatic cholestasis, bile duct deficiency and absence of cholic acid from bile.
Aliases: RACE
- Molekulargewicht
- 42kDa
- Gen-ID
- 23600
- HGNC
- 23600
- UniProt
- Q9UHK6
- Pathways
- Monocarboxylic Acid Catabolic Process
-